Provectus Biopharmaceuticals (PVCT) Short Interest Ratio & Short Volume $0.12 -0.01 (-7.26%) (As of 12/20/2024 05:55 PM ET) Add Compare Share Share Short Interest Stock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Provectus Biopharmaceuticals Short Interest DataProvectus Biopharmaceuticals (PVCT) has a short interest of 2,700 shares. This marks a 440.00% increase in short interest from the previous month. The short interest ratio (days to cover) is 0.0, indicating that it would take 0.0 days of the average trading volume of 257,567 shares to cover all short positions.Current Short Interest2,700 sharesPrevious Short Interest500 sharesChange Vs. Previous Month+440.00%Dollar Volume Sold Short$318.60Short Interest Ratio0.0 Days to CoverLast Record DateNovember 30, 2024Outstanding Shares438,086,000 sharesPercentage of Shares Shorted0.00%Today's Trading Volume96,909 sharesAverage Trading Volume257,567 sharesToday's Volume Vs. Average38% Short Selling Provectus Biopharmaceuticals? Sign up to receive the latest short interest report for Provectus Biopharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartPVCT Short Interest Over TimePVCT Days to Cover Over TimePVCT Percentage of Float Shorted Over Time Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Provectus Biopharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/30/20242,700 shares $318.60 +440.0%N/A0 $0.12 11/15/2024500 shares $55.05 -99.2%N/A0 $0.11 10/31/202465,600 shares $7,052.00 +1,626.3%N/A0.2 $0.11 10/15/20243,800 shares $410.02 -93.5%N/A0 $0.11 9/30/202458,700 shares $5,746.73 +3,568.8%N/A0.1 $0.10 9/15/20241,600 shares $159.76 -48.4%N/A0 $0.10 Get the Latest News and Ratings for PVCT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Provectus Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 8/31/20243,100 shares $279.00 -91.8%N/A0 $0.09 8/15/202437,800 shares $3,277.26 +404.0%N/A0.1 $0.09 7/31/20247,500 shares $768.75 +87.5%N/A0 $0.10 7/15/20244,000 shares $458.80 +700.0%N/A0 $0.11 6/30/2024500 shares $63.05 No ChangeN/A0 $0.13 6/15/2024500 shares $79.50 -87.8%N/A0 $0.16 5/31/20244,100 shares $690.03 +720.0%N/A0 $0.17 5/15/2024500 shares $97.15 -99.7%N/A0 $0.19 4/30/2024142,600 shares $28,377.40 +127.8%N/A0.4 $0.20 4/15/202462,600 shares $10,485.50 -67.2%N/A0.1 $0.17 3/31/2024190,800 shares $34,887.78 +1,700.0%N/A0.3 $0.18 3/15/202410,600 shares $2,299.14 -85.7%N/A0 $0.22 2/29/202474,000 shares $11,003.80 -4.0%N/A0.2 $0.15 2/15/202477,100 shares $10,470.18 +1,780.5%N/A0.2 $0.14 1/15/202416,300 shares $1,677.27 -50.6%N/A0.1 $0.10 12/31/202333,000 shares $3,168.00 +89.7%N/A0.1 $0.10 12/15/202317,400 shares $1,896.60 +3.0%N/A0 $0.11 11/30/202316,900 shares $2,535.00 -46.5%N/A0 $0.15 11/15/202331,600 shares $4,740.00 +179.7%N/A0 $0.15 10/31/202311,300 shares $904.00 +2,160.0%N/A0 $0.08 10/15/2023500 shares $35.00 No ChangeN/A0 $0.07 9/30/2023500 shares $42.25 -94.8%N/A0 $0.08 9/15/20239,600 shares $943.68 +100.0%N/A0.1 $0.10 8/31/20234,800 shares $489.60 -46.1%N/A0 $0.10 8/15/20238,900 shares $845.50 +1,680.0%N/A0 $0.10 7/31/2023500 shares $54.45 -97.8%N/A0 $0.11 7/15/202322,300 shares $2,796.42 -64.6%N/A0.1 $0.13 6/30/202363,000 shares $7,125.30 +63.6%N/A0.1 $0.11 6/15/202338,500 shares $4,581.50 +7,600.0%N/A0.1 $0.12 5/31/2023500 shares $67.95 -99.4%N/A0 $0.14 5/15/202381,400 shares $11,387.86 +13,466.7%N/A0.4 $0.14 4/30/2023600 shares $80.22 -81.3%N/A0 $0.13 4/15/20233,200 shares $489.60 -96.4%N/A0 $0.15 3/31/202389,000 shares $14,685.00 +88,900.0%N/A0.3 $0.17AI breakthrough about to upend industry (Ad)Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.I urge you to watch it now. 3/15/2023100 shares $15.40 -99.9%N/A0 $0.15 2/28/2023116,600 shares $18,772.60 +3,051.4%N/A0.3 $0.16 2/15/20233,700 shares $395.53 -89.5%N/A0 $0.11 1/31/202335,200 shares $4,509.12 +262.9%N/A0.1 $0.13 1/15/20239,700 shares $1,286.71 +9,600.0%N/A0 $0.13 12/30/2022100 shares $10.83 -99.0%N/A0 $0.11 12/15/202210,000 shares $1,099.00 -66.6%N/A0 $0.11 11/30/202229,900 shares $2,780.70 -45.5%N/A0 $0.09 11/15/202254,900 shares $2,843.82 +54,800.0%N/A0.1 $0.05 10/31/2022100 shares $5.00 No ChangeN/A0 $0.05 10/15/2022100 shares $4.85 No ChangeN/A0 $0.05 9/30/2022100 shares $4.90 -99.6%N/A0 $0.05 9/15/202225,500 shares $1,351.50 +8.5%N/A0.1 $0.05 8/31/202223,500 shares $1,280.75 +2,511.1%N/A0.1 $0.05 8/15/2022900 shares $49.50 +80.0%N/A0 $0.06 7/31/2022500 shares $29.00 +400.0%N/A0 $0.06 7/15/2022100 shares $5.99 -99.6%N/A0 $0.06 6/30/202226,200 shares $1,419.28 +26,100.0%N/A0.1 $0.05 6/15/2022100 shares $5.30 -96.8%N/A0 $0.05 5/31/20223,100 shares $186.00 -54.4%N/A0 $0.06 5/15/20226,800 shares $357.68 +3,300.0%N/A0 $0.05 4/30/2022200 shares $12.28 +100.0%N/A0 $0.06 4/15/2022100 shares $5.86 No ChangeN/A0 $0.06 3/31/2022100 shares $6.74 No ChangeN/A0 $0.07 3/15/2022100 shares $6.92 -96.7%N/A0 $0.07 2/28/20223,000 shares $206.70 +2,900.0%N/A0 $0.07 2/15/2022100 shares $7.00 -98.7%N/A0 $0.07 1/31/20227,700 shares $500.50 -85.4%N/A0 $0.07 1/15/202252,600 shares $3,682.00 +39.2%N/A0.1 $0.07 12/31/202137,800 shares $2,079.00 +37,700.0%N/A0 $0.06 12/15/2021100 shares $5.03 -93.8%N/A0 $0.05 11/30/20211,600 shares $85.76 -61.0%N/A0 $0.05 11/15/20214,100 shares $213.61 +4,000.0%N/A0 $0.05 10/29/2021100 shares $5.62 -99.9%N/A0 $0.06 10/15/202190,700 shares $5,587.12 -24.6%N/A0.4 $0.06 9/30/2021120,300 shares $7,819.50 +55.8%N/A0.3 $0.07 9/15/202177,200 shares $4,863.60 -45.4%N/A0.2 $0.06 8/31/2021141,300 shares $8,619.30 -29.4%N/A0.1 $0.06 8/13/2021200,200 shares $13,913.90 -22.3%N/A0.5 $0.07 7/30/2021257,500 shares $17,896.25 +29.7%N/A1 $0.07 7/15/2021198,600 shares $13,902.00 +13.6%N/A0.4 $0.07 6/30/2021174,900 shares $11,980.65 -3.6%N/A0.7 $0.07 6/15/2021181,500 shares $12,668.70 -10.4%N/A0.3 $0.07 5/28/2021202,600 shares $14,911.36 +9.0%N/A0.5 $0.07 5/14/2021185,800 shares $12,430.02 +16.1%N/A0.6 $0.07 4/30/2021160,000 shares $10,400.00 No ChangeN/A0.3 $0.07 4/15/2021160,000 shares $10,752.00 -14.5%N/A0.5 $0.07 3/31/2021187,200 shares $13,122.72 +10.1%N/A0.3 $0.07 3/15/2021170,000 shares $11,645.00 +6.3%N/A0.5 $0.07 2/26/2021160,000 shares $11,680.00 -34.0%N/A0.3 $0.07AI breakthrough about to upend industry (Ad)Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.I urge you to watch it now. 2/12/2021242,400 shares $17,695.20 +25.9%N/A0.3 $0.07 1/29/2021192,600 shares $14,445.00 -54.3%N/A0.1 $0.08 1/15/2021299,400 shares $20,898.12 +76.1%N/A0.4 $0.07 12/31/2020160,500 shares $9,292.95 -46.4%N/A0.3 $0.06 12/15/2020299,400 shares $17,514.90 +76.1%N/A0.4 $0.06 11/30/2020170,000 shares $10,880.00 -1.4%N/A0.3 $0.06 11/15/2020172,400 shares $11,585.28 -46.8%N/A0.6 $0.07 10/30/2020324,100 shares $22,038.80 +23.8%N/A0.9 $0.07 10/15/2020261,700 shares $19,889.20 -44.8%N/A0.5 $0.08 9/30/2020473,700 shares $41,022.42 +194.6%N/A0.7 $0.09 9/15/2020160,800 shares $11,674.08 +0.2%N/A0.4 $0.07 8/31/2020160,500 shares $12,968.40 -42.0%N/A0.3 $0.08 8/14/2020276,700 shares $26,148.15 +3,493.5%N/A0.2 $0.09 7/31/20207,700 shares $553.63 -67.4%N/A0 $0.07 7/15/202023,600 shares $1,413.64 +81.5%N/A0.1 $0.06 6/30/202013,000 shares $585.00 +20.4%N/A0 $0.05 6/15/202010,800 shares $509.76 +2,060.0%N/A0 $0.05 5/29/2020500 shares $22.30 -80.0%N/A0 $0.04 5/15/20202,500 shares $105.25 +400.0%N/A0 $0.04 4/30/2020500 shares $21.00 No ChangeN/A0 $0.04 4/15/2020500 shares $24.15 -99.2%N/A0 $0.05 3/31/202061,000 shares $2,440.00 +634.9%N/A0.1 $0.04 3/13/20208,300 shares $498.00 +45.6%N/A0 $0.06 2/28/20205,700 shares $171.00 -79.2%N/A0 $0.03 2/14/202027,400 shares $1,096.00 +103.0%N/A0 $0.04 1/31/202013,500 shares $810.00 -2.2%N/A0 $0.06 1/15/202013,800 shares $924.60 -33.3%N/A0 $0.07 12/31/201920,700 shares $1,242.00 -95.9%N/A0 $0.06 PVCT Short Interest - Frequently Asked Questions What is Provectus Biopharmaceuticals' current short interest? Short interest is the volume of Provectus Biopharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of November 30th, traders have sold 2,700 shares of PVCT short. Learn More on Provectus Biopharmaceuticals' current short interest. Is Provectus Biopharmaceuticals' short interest increasing or decreasing? Provectus Biopharmaceuticals saw a increase in short interest in the month of November. As of November 30th, there was short interest totaling 2,700 shares, an increase of 440.0% from the previous total of 500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Provectus Biopharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Provectus Biopharmaceuticals: Tenaya Therapeutics, Inc. (21.42%), Fate Therapeutics, Inc. (9.97%), DiaMedica Therapeutics Inc. (0.35%), Atai Life Sciences (8.71%), Zentalis Pharmaceuticals, Inc. (6.55%), Acrivon Therapeutics, Inc. (5.07%), Molecular Partners AG (0.15%), Aclaris Therapeutics, Inc. (3.47%), Biomea Fusion, Inc. (31.36%), SOPHiA GENETICS SA (0.06%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.55 billion), Spotify Technology S.A. ($3.84 billion), Royal Caribbean Cruises Ltd. ($3.07 billion), International Paper ($3.00 billion), Coinbase Global, Inc. ($2.93 billion), Cencora, Inc. ($2.54 billion), Paychex, Inc. ($2.53 billion), SoFi Technologies, Inc. ($2.24 billion), and Reddit, Inc. ($2.00 billion). View all of the most shorted stocks. What does it mean to sell short Provectus Biopharmaceuticals stock? Short selling PVCT is an investing strategy that aims to generate trading profit from Provectus Biopharmaceuticals as its price is falling. PVCT shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Provectus Biopharmaceuticals? A short squeeze for Provectus Biopharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of PVCT, which in turn drives the price of the stock up even further. How often is Provectus Biopharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PVCT, twice per month. The most recent reporting period available is November, 30 2024. More Short Interest Resources from MarketBeat Related Companies TNYA Short Interest Data FATE Short Interest Data DMAC Short Interest Data ATAI Short Interest Data ZNTL Short Interest Data ACRV Short Interest Data MOLN Short Interest Data ACRS Short Interest Data BMEA Short Interest Data SOPH Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (OTCMKTS:PVCT) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Provectus Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Provectus Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PVCT Stock Alerts